UCL's Freeline Therapeutics has priced its shares at $18 to raise nearly $159m through an IPO on the Nasdaq Global Select Market.

Freeline Therapeutics, a UK-based gene therapy developer based on University College London (UCL) research, has priced its shares at $18 and will raise almost $159m when it goes public today.
The company issued more than 8.8 million American Depositary Shares (ADSs), representing the same number of ordinary shares. Commercialisation firm Syncona invested $24.3m in the initial public offering and Freeline will trade on the Nasdaq Global Select Market using the ticker symbol FRLN.
Founded in 2015 by Syncona,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in